Drug Stock Crushed By Short Seller Report

Kerrisdale Capital thinks PTI shares can fall up to 90%

Mar 20, 2018 at 1:56 PM
facebook twitter linkedin

The Dow is set for a nice win today, thanks in part to rising oil prices. Three stocks making notable moves are drugmakers Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Marinus Pharmaceuticals Inc (NASDAQ:MRNS), and Proteostasis Therapeutics Inc (NASDAQ:PTI). Let's take a closer look at what's moving shares of ARNA, MRNS, and PTI.

Trial Results Drive ARNA Near Top of Nasdaq

ARNA stock is trading up 30% at $40.20 -- one of the top Nasdaq gainers today -- after the company released positive mid-stage trial data for its chronic bowel disease drug. This news prompted price-target hikes from Cantor Fitzgerald ($64) and Leerink ($63). Looking back, Arena Pharmaceuticals had been in an impressive uptrend until a sharp sell-off last week, with the shares earlier topping out just below their March 5 two-year high of $44.50. The security certainly has the backing of Wall Street, with five of the six covering analysts handing out "strong buy" recommendations.

Mizuho Gives Struggling MRNS a Bump

A fresh "buy" rating and $13 price target at Mizuho has shares of MRNS up 10.6% at $4.52. The stock needed the bounce, as it'd been trending lower since its December peak near $10. It earlier broke above the 20-day moving average for the first time since early February -- though it's already moved back below this level. At the same time, Marinus was trading near just $1.50 this time last year.

Meanwhile, some short sellers have been exiting positions. Specifically, short interest fell by 17.8% over the last two reporting periods.

Kerrisdale Capital Goes Short On PTI Stock

Proteostasis Therapeutics has dropped 22.5% to trade at $5.42, after the company announced a public stock offering of 9 million shares. Plus, Kerrisdale Capital said it's shorting PTI, adding the drugmaker's cystic fibrosis treatment isn't as impressive as it appears, while calling for downside of 70%-90%. This puts PTI shares back below their year-to-date breakeven of $5.83, though they remain well above their 52-week low of $1.41. The equity may have been due for a pullback regardless, given its 14-day Relative Strength Index (RSI) of 81 at yesterday's close -- deep in overbought territory. 


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!